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Abstract
Bipolar disorder (BD) is highly heterogeneous in symptomatology. Narrowing the clinical phenotype may increase the
power to identify risk genes that contribute to particular BD subtypes. This study was designed to test the hypothesis
that genetic overlap between schizophrenia (SZ) and BD is higher for BD with a history of manic psychosis. Analyses
were conducted using a Mayo Clinic Bipolar Biobank cohort of 957 bipolar cases (including 333 with history of
psychosis during mania, 64 with history of psychosis only during depression, 547 with no history of psychosis, and 13
with unknown history of psychosis) and 778 controls. Polygenic risk score (PRS) analysis was performed by calculating
a SZ-PRS for the BD cases and controls, and comparing the calculated SZ risk between different psychosis subgroups
and bipolar types. The SZ-PRS was significantly higher for BD-I cases with manic psychosis than BD-I cases with
depressive psychosis (Nagelkerke’s R2= 0.021; p= 0.045), BD-I cases without psychosis (R2= 0.015; p= 0.007), BD-II
cases without psychosis (R2= 0.014; p= 0.017), and controls (R2= 0.065; p= 2 × 10−13). No other significant
differences were found. Our results show that BD-I with manic psychosis is genetically more similar to SZ than any
other tested BD subgroup. Further investigations on genetics of distinct clinical phenotypes composing major
psychoses may help refine the current diagnostic classification system.
Introduction
Bipolar disorder (BD) is a highly heterogeneous illness,
which presents clinical challenges and likely contributes
to difficulties in identifying genetic underpinnings of this
disorder1–3. It has been postulated that classifying BD
sub-phenotypes based on clinical characteristics may help
uncover underlying genetic risk factors of more geneti-
cally homogeneous disease subtypes3,4.
Since Kraepelin et al.5 described manic-depression and
dementia praecox as two separate psychotic disorders,
this dichotomy persisted as a part of clinical nosology5.
However, there is accumulating evidence that these two
disorders overlap in neuroimaging, neuropsychological,
histological, and clinical features6–10. Previous studies
have also consistently shown shared genetic etiology
between BD and schizophrenia (SZ)11–17. Studies
addressing the genetic overlap between BD and SZ have
evolved from studying family and twin inheritance to
estimating genetic correlation and performing polygenic
risk score (PRS) analysis using genome-wide association
data from large case–control samples. In a PRS analysis,
single-nucleotide polymorphism (SNP) effect sizes from a
prior genome-wide association study (GWAS) of “disease
A” (e.g., SZ) can be used to calculate the estimated risk of
“disease A” for a group of controls and patients with
“disease B” (e.g., BD) to evaluate whether on average
patients with “disease B” (i.e., BD, in our example) have
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elevated genetic risk of “disease A” (i.e., SZ, in our
example). Evidence of this elevated genetic risk suggests
the two diseases have overlapping genetic predisposition.
There are at least four published PRS studies investigating
the overlap between SZ and BD in the context of clinical
sub-phenotypes. Ruderfer et al.18,19 showed that a poly-
genic BD signature is correlated with developing mania in
SZ, and that psychotic features in BD have a significant
genetic correlation with SZ. Hamshere et al.20 found that
subjects with schizoaffective BP (SZBP) carry an excess of
SZ-associated alleles compared to non-SZBP subjects.
Finally, Allardayce et al.21 showed a gradient of SZ-PRS in
the following order SZBP > BD-I with mood-incongruent
psychosis > BD-I with mood congruent psychosis > BD-I
without psychosis > BD-II.
In addition to growing recognition that BD with psy-
chosis has a higher SZ-PRS compared to non-psychotic
BD, there is also increasing evidence that depression and
mania in BD have different genetic underpinnings22,23. In
this study, we therefore hypothesized that psychoses
found on the opposite poles of the BD spectrum, that is,
manic and depressive psychoses, will differ in terms of SZ-
PRS. These BD sub-phenotypes have never been studied
using SZ-PRS and are important to understand as BD
with psychosis carries particularly high morbidity24,25.
Patients and methods
Participants
Patients with BP were drawn from the Mayo Clinic
Bipolar Biobank26. This biobank was established in 2009
with a primary goal to build a biorepository to study
disease risk and treatment outcome22. Enrollment sites
included Mayo Clinic, Rochester, Minnesota; Lindner
Center of HOPE/University of Cincinnati College of
Medicine, Cincinnati, Ohio; and the University of Min-
nesota, Minneapolis, Minnesota. Enrollment at each site
was approved by the local Institutional Review Board, and
all participants consented to use of their data for future
genetic studies. Participants were identified through
routine clinical appointments, from in-patients admitted
in mood disorder units, and recruitment advertising.
Cases were required to be between 18 and 80 years old
and be able to speak English, provide informed consent,
and have Diagnostic and Statistical Manual of Mental
Disorders IV-TR diagnostic confirmation of BD-I or BD-
II as determined by using the Structured Clinical Inter-
view for DSM-IV (SCID)27. Patients who were presently
psychotic or suicidal were not enrolled. Patients were
assessed for a history of psychosis during manic episodes
and/or depressive episodes using the SCID. In total, 1046
cases from the Bipolar Biobank were genotyped. Controls
(n= 828) were selected from the Mayo Clinic Biobank28.
Potential controls with International Classification of
Disease-9 codes for BD or SZ in their electronic medical
record were excluded. Clinical Questionnaire was used to
obtain data on medications taken at the time of blood
collection.
Genotyping, imputation, and control for population
stratification
The Illumina HumanOmniExpress platform was used
to genotype 1046 BD cases and 828 controls (N= 1874;
730,499 SNPs). For quality control purposes, we excluded
subjects with <98% call rate and related subjects (by
including only one subject from each pair with estimated
identical-by-descent allele sharing >0.2), and SNPs with
call rate <98%, minor allele frequency (MAF) <0.01, and
SNPs not in Hardy–Weinberg equilibrium (P < 1e−06).
After these steps, 643,011 SNPs and 1478 subjects
remained. We also performed principal component (PC)
analysis in this subset; subsequent PRS analyses were
adjusted for four PCs that were associated with the
case–control status.
SNP imputation was performed using IMPUTE2.2.229
with the 1000 genome project reference data (phase 1
data, all populations). SNPs with dosage R2 < 0.3 (poor
quality imputation), and those with MAF < 0.01 (rare
alleles) were removed, resulting in 7,999,324 SNPs that
were included in the analysis. After quality control of
genetic and clinical data, the genetic analyses included
957 cases (696 BD-I, 261 BD-II patients) and 778 controls.
Phenotype definition
Patients were assessed for a history of psychosis during
manic episodes or psychosis during depressive episodes
using the SCID. Of the 957 cases, 333 (by definition BD-I)
had a history of manic psychosis, 64 (42 BD-I; 22 BD-II)
had a history of psychosis only during depression, 547
(312 BD-I; 235 BD-II) cases had no history of psychosis,
and 13 (9 BD-I; 4 BD-II) had insufficient information to
reliably determine their history of psychosis. Only 40
cases had psychosis during both mania and depression
and were assigned to the manic psychosis group for the
analysis. These cases were also analyzed as a separate
group in a supplementary analysis.
Polygenic risk score
We constructed polygenic risk scores (PRS)12 in our
sample using the PRSice software30 based on common
SNP risk effects derived from summary statistics from a
large SZ GWAS conducted by the Psychiatric Genomics
Consortium (PGC-SZ)31. In order to account for linkage
disequilibrium (LD) among SNPs, clumping was per-
formed in PLINK v1.90b3v32 to select relatively inde-
pendent SNPs (clump-r2 was set to 0.1, and the block size
threshold clump-kb to 250). In the comparison of all BD
cases vs. controls, we evaluated a series of PGC-SZ
association p value thresholds from 0.0005 to 0.5 by
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increments of 0.0005. A p value threshold of 0.039 per-
formed best in our sample in the BD case–control com-
parisons, and was used subsequently for all other
subgroup comparisons. The PRS for SZ (SZ-PRS) was
standardized using its mean in the BD cases with no
psychosis and the standard deviation (SD) in all subjects
so that the cases without psychosis serve as a reference
group for all comparisons. Therefore, the effect sizes in
the linear regression are standardized and can be inter-
preted as a mean difference in standardized scores.
Statistical analysis
We compared the mean SZ-PRS of different subgroups
using linear regression with the risk score as the outcome
and subgroup indicator variables as predictors. In addi-
tion, to calculate Nagelkerke’s R2, a commonly reported
measure of effect size in PRS analyses, we also used
logistic regression with the sub-phenotype of interest as
the outcome. All analyses were performed in R (version
3.2) and were adjusted for the first four PCs to account for
potential population stratification. We first compared all
case subgroups described in the columns of Table 1 and
the 778 controls. We next further divided our psychosis
subgroups by bipolar type (BD-I or BD-II) and compared
BD-I cases with manic psychosis to BD-I cases with
depressive psychosis, BD-I without history of psychosis,
and BD-II cases without psychosis. Other subgroups were
not compared due to small sample sizes.
Results
Sample description
Table 1 summarizes the demographic and medication
information of clinically defined groups included in this
study. Of the 944 cases that could be assessed for history
of psychosis, 570 (60%) were female. The mean age at the
time of blood draw was 42.8 years (SD= 15.2). Consistent
with our phenotype definition, cases without psychosis
were taking significantly less antipsychotic medications at
the time of biobank enrollment than cases with depressive
psychosis (p= 0.003) or cases with manic psychosis (p=
2 × 10−10). Cases with depressive psychosis were taking
significantly more antidepressant medications than cases
with manic psychosis (p= 0.013).
Polygenic risk score analysis
Table 2 shows the results of the SZ-PRS comparisons
between groups, as well as the proportion of variance in
the phenotypes explained by the PRS (Nagelkerke’s R2).
The PRS analysis comparing all Mayo BD-I and BD-II
cases (n= 957) with controls (n= 778) showed evidence
for association between SZ genetic risk and BD (p= 2 ×
10−12). However, no difference in SZ risk between BD-I
and BD-II cases was found (p= 0.21). Figure 1 shows the
unadjusted SZ-PRS for each subgroup after stratifying BD
cases into sub-phenotypes without psychosis (n= 547, of
which 312 had BD-I and 235 had BD-II), with psychosis
during only depression (n= 64, of which 42 had BD-I and
22 had BD-II), and with psychosis during mania (n= 333,
consisting of only BD-I). In the PC-adjusted model
comparing subgroups without psychosis, depressive psy-
chosis, and manic psychosis to controls, the mean SZ-PRS
was 0.26 (p= 8 × 10−7), 0.20 (p= 0.103), and 0.46 (p=
2 × 10−13) SDs higher than controls, respectively. In our
case-only analysis, cases with no psychosis and cases with
psychosis during mania had significantly different adjus-
ted mean SZ-PRS (p= 0.0027). Cases with psychosis
during mania also had significantly higher SZ-PRS than
cases with psychosis during only depression (p= 0.043).
The above conclusions did not change when the cases
with psychosis during both depression and mania (n= 40)
were analyzed separately rather than assigned to the
manic psychosis group (Supplementary Figure 1).
Because only BD-I cases can be diagnosed with psy-
chosis during mania, and because previous studies have
Table 1 Demographic information for cases
All, N= 944 No psychosis, N= 547 Depressive psychosis, N= 64 Manic psychosis, N= 333
Age, mean (SD) 42.8 (15.2) 43.1 (15.7) 43.3 (15.2) 42.7 (14.5)
Sex
Male 387 (40.4%) 224 (41.0%) 20 (31.2%) 138 (41.4%)
Female 570 (59.6%) 323 (59.0%) 44 (68.8%) 195 (58.6%)
Bipolar disorder
Type I 696 (72.7%) 312 (57.0%) 42 (65.6%) 333 (100%)
Type II 261 (27.3%) 235 (43.0%) 22 (34.4%) 0
Current medications
Lithium 304 (31.8%) 157 (28.7%) 17 (26.6%) 126 (37.8%)
Anti-psychotics 437 (45.7%) 200 (36.6%) 36 (56.2%) 196 (58.9%)
Anti-depressants 411 (43.0%) 249 (45.5%) 35 (54.7%) 124 (37.2%)
Total medicationsa, mean (SD) 1.29 (0.94) 1.19 (0.92) 1.48 (0.94) 1.44 (0.96)
BD bipolar disorder, SZ schizophrenia, SD standard deviation
aSum of the above medications
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shown higher SZ-PRS in BD-I than in BD-II patients21,33,
we further divided our psychosis sub-phenotype by type
of BD (Fig. 2). The differences described above increased
so that the BD-I cases with psychosis during mania had
0.20 SD (p= 0.007) and 0.31 SD (p= 0.045) higher PC-
adjusted mean SZ-PRS than BD-I cases without psychosis
and with psychosis during depression, respectively. BD-I
cases with manic psychosis also had a 0.19 SD (p= 0.017)
higher PC-adjusted mean risk of SZ than BD-II cases
without psychosis. In short, BD-I subjects with manic
psychosis had 0.21 SD (p= 0.015) and 0.19 SD (p= 0.003)
higher adjusted SZ risk than any other BD-I subject or
BD-II subject group, respectively. There were no sig-
nificant differences in SZ genetic risk between cases
without psychosis and cases with psychosis during only
depression in either analysis.
Discussion
Our results show that SZ-PRS is a better predictor of
BD with manic psychosis than of BD with only depressive
psychosis or no history of psychosis. This suggests that
BD patients with manic psychosis are genetically more
similar to SZ than BD patients with a history of only
depressive psychosis or BD patients with no occurrence of
psychosis. Previous studies have shown higher mean SZ
PRSs in BD-I than in BD-II, and in BD with psychosis
than in BD without psychosis33. In addition, a gradient of
SZ-PRS in patients with BD was shown in the following
order SZBP > BD-I with mood-incongruent psychosis >
BD-I with mood congruent psychosis > BD-I without
psychosis > BD-II21. Our results are consistent with these
findings and further suggest that SZ-PRS is higher in BD
with manic psychosis, than in BD without psychosis or
with psychosis during depression. Together with pre-
viously published PRS studies, these results further erode
the traditional dichotomy between BD and SZ.
We did not find a significant difference in SZ-PRS
between the BD-I and BD-II groups, which was previously
shown by Charney et al33. However, we note that the
effect size estimate for this comparison is identical in our
study and in the study of Charney et al.33 (R2= 0.003 in
both studies), indicating our results are consistent with
those of Charney et al.,33 and our results did not achieve
statistical significance due to the smaller sample size.
Table 2 Association of polygenic risk scores across variously defined bipolar strata
Est (95% CI) p value Nagelkerke’s R2
Comparison to 778 controls
BD case (N= 958) 0.33 (0.24, 0.42) 2.0e−12 0.038
Stratified by type
BD type I (N= 696) 0.35 (0.25, 0.45) 2.8e−12 0.044
BD type II (N= 261) 0.26 (0.13, 0.40) 9.8e−05 0.021
Stratified by psychosis subtype
Manic psychosis (N= 333) 0.46 (0.34, 0.58) 2.1e−13 0.065
Depressive psychosis (N= 64) 0.20 (−0.04, 0.44) 0.103 0.007
No psychosis (N= 547) 0.26 (0.16, 0.37) 7.6e−07 0.025
Within-case comparisons
Manic psychosis vs. no psychosis 0.20 (0.07, 0.32) 0.003 0.014
Depressive psychosis vs. no psychosis −0.06 (−0.31, 0.18) 0.611 0.001
Manic psychosis vs. depressive psychosis 0.26 (0.01, 0.51) 0.043 0.016
Split by BD type
BD-I vs. BD-II 0.09 (−0.05, 0.22) 0.209 0.003
Manic psych vs. BD-I-no psych (N= 312) 0.20 (0.05, 0.34) 0.007 0.015
BD-I-dep psych (N= 42) vs. BD-I-no psych −0.11 (−0.41, 0.19) 0.481 0.005
Manic psychosis vs. BD-I-dep psychosis 0.31 (0.01, 0.61) 0.045 0.021
Manic psych vs. BD-II-no psych (N= 235) 0.19 (0.03, 0.35) 0.017 0.014
BD-I-no psych vs. BD-II-no psych −0.01 (−0.17, 0.15) 0.922 6 × 10−5
BD bipolar disorder, Psych psychosis, Est estimated difference of standardized polygenic risk scores between the two groups, CI confidence interval, Est, CI, p value are
based on linear regreesion with PRS as the outcome
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However, our results further suggest that the small dif-
ference in SZ-PRS observed between BD-I and BD-II
cases in both our data and the data of Charney is likely
largely driven by the subset of BD-I cases with psychosis
during mania that compose part of the total BD-I group
and have the highest SZ genetic risk scores. Our study was
the first to consider BD type (I vs. II) and psychosis type
(psychosis during mania vs. psychosis during depression
vs. no psychosis) simultaneously, and our study suggests
that SZ-PRS is not very different in BD-I without psy-
chosis and BD-II without psychosis (Table 2). Replication
of this finding in larger samples is warranted.
Our results should be interpreted in the context of the
study’s limitations. First, the number of patients with
depressive psychosis was relatively small leading to low
power in comparisons involving this group. In particular,
our study had 80% power to find differences of about
0.4 SD in the mean standardized PRS in comparisons with
this group, whereas we had 80% power to detect differ-
ences as small as 0.2 SDs when comparing standardized
PRSs in the manic psychosis group vs. the BD with no
psychosis or control groups. Nevertheless, despite this
power limitation, our study provided marginally sig-
nificant evidence that SZ-PRS is lower in BD patients with
psychosis during depression than in BD patients with
psychosis during mania (p= 0.043). Age or duration of
illness may also have influenced our results, since some of
the young non-psychotic BD patients may potentially
experience manic psychosis in the future. However, on
average the manic psychosis patients were slightly
younger than the patients who have not experienced
psychosis, suggesting that this bias was not likely to have
played an important role. Finally, multiple p value
thresholds were used to optimize the SZ-PRS for the
comparison of the full set of cases vs. controls; therefore,
the threshold for statistical significance for any
case–control comparison should be more stringent30.
However, we note that the PRS was not further optimized
for any within-case comparisons; thus no further adjust-
ment for multiple testing would be required for these
comparisons. Nevertheless, pairwise comparisons among
multiple case subgroups were performed, which should be
taken into account in interpreting the results.
Overall, our results add to the concept that SZ and BD
are on a spectrum of continuously distributed genetic and
phenotypic variables, rather than being two entirely dis-
crete disorders. Our findings point to a cumulative effect
of “SZ alleles” that at higher frequencies shift bipolar
Fig. 1 The unadjusted standardized PRS derived from PGC-SZ are plotted for controls and cases (from left to right) with no history of
psychosis, psychosis during only depression, and psychosis during mania. The y-axis shows the standardized SZ-PRS score. The mean PRS and
subgroup sample size are printed above and below each boxplot, respectively. Significance of comparisons between groups after adjustment for
principal components are shown above (ns= not significant, *<0.05, **<0.01, ***<0.001, ****<0.0001)
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presentation more towards psychotic mania. These find-
ings could help shape future diagnostic reclassification of
major psychoses.
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